Baseline and periodic bone density scans can detect changes before they become serious
Ongoing research into nutritional and exercise interventions, as well as novel pharmacological agents such as myostatin/activin pathway inhibitors (243) or agents targeting the apelin pathway (244) holds promise for preserving lean mass and improving overall health in patients undergoing treatment with GLP-1 and dual GIP/GLP-1 receptor agonists
Tennis elbow exists on a spectrum from acute inflammation to chronic degenerative changes
The key insight is that cumulative progress over 48 weeks produces dramatic, life-changing results even if individual weeks feel slow or frustrating
Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118)
The Study: Real-World Weight Loss Outcomes Researchers analyzed data from over 50,000 adults with obesity: 38,545 patients received a GLP-1 medication such as semaglutide or tirzepatide 12,540 patients underwent bariatric surgery, primarily gastric bypass or sleeve gastrectomy Key Findings : Surgery patients lost an average of 24% of their body weight over two years about 58 pounds